clinical trial · NCT06681766
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
Friedreich AtaxiaNomlabofuspPlacebo
brief summary
The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
started
Dec 6, 2024
primary completion
Apr 28, 2025
completion
Apr 28, 2025
last updated
Jan 28, 2026
detailed description
This is a randomized, double-blind, placebo-controlled study evaluating a weight-based dose of nomlabofusp versus placebo in adolescents and children with FRDA. The study will consist of at least two cohorts with at least 12 to 15 participants in each cohort. Participants will be dosed once daily (QD) for 7 days.
official title
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol